The FDA has approved tazemetostat for treating epithelioid sarcoma. The drug produced responses in 15% of patients with the disease in a phase II trial, and 67% of the responses lasted at least 6 months. The drug is the first targeted treatment for epithelioid sarcoma.

©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.